Eli Lilly is a global pharmaceutical company, developing a new drug for the treatment of obesity and type 2 diabetes. The drug, known as tirzepatide, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is intended to help patients with type 2 diabetes lose weight and improve their glycemic control. Tirzepatide is currently in phase 3 clinical trials and has shown promising results so far. The Need for a Diabetes Drug for Weight Loss Obesity is a major risk factor for type 2 diabetes, and both conditions are becoming increasingly…